[ET Net News Agency, 11 March 2026] Morgan Stanley lowered the target price for
Genscript Bio (01548) to HKD16.5 from HKD18.3 and maintained the "overweight" rating.
The research house said in view of the preliminary 2025 release, it cuts 2026-2030
earnings estimates by 1-13%. (rc)